A very important result from the EUPATI project was the development, broad consultation and final release of guidances on the best approach to interaction of patients with pharmaceutical industry-led...
Transcription Of course, my name’s Ross Carroll. I’m the Public Affairs Director for the UK and Ireland for UCB pharma. Within that role, I’m responsible...
Participant adherence is an essential part of every clinical trial and means ‘the extent to which participants follow the instructions they have been given for participating in the clinical...
Transcription I’m Gilli Spurrier-Bernard. I am a patient advocate because my husband is a stage 4 melanoma patient. As a patient advocate I initiated...
The term 'personalised medicine' includes both stratification and personalisation, which are often incorrectly used as synonyms. However, the two are different, as explained further below.
When women of childbearing potential are included in clinical trials, safety precautions must be taken in order to avoid the unintentional exposure of an embryo or fetus to the...
After Phase III of clinical studies, all the information on a medicin is collected and organised in a pre-determiend format (a dossier), which is then submitted to the regulatory...
Data from non-clinical trials is important as a predictor and decision-making tool in the medicines development process. Adequate and satisfactory non-clinical results are required before a medicine may be...
Note: This webinar took place on 28 June 2018. You can find a video recording and the presentations used during the webinar below. Webinar introduction Community advisory...
